Is Colgate-Palmolive a Buy?

Colgate-Palmolive (NYSE: CL) has proved remarkably resilient during the pandemic as first-quarter sales rose 5.5% from last year and profits bounded 28% higher. Because the personal care products giant generates around 70% of its revenue from international markets, and 45% of total sales came from emerging markets in the first quarter, its business has performed admirably despite widespread exposure to the impacts caused by the coronavirus. A good part of Colgate-Palmolive's ability to withstand the storm has been the strength of its portfolio of brands, which often occupy the top one or two spots in any given category.